Questionable Marketing of Neurontin
Marketed by Pfizer Inc., Neurontin (gabapentin) is used to treat partial seizures, or epilepsy, in adults and children.
A jury in March 2010 found that Pfizer violated U.S. racketeering law in the marketing of Neurontin and was ordered to pay $142.1 million in damages, a jury decided.
Patients who have used Neurontin for non-FDA approved use have been found to be at an elevated risk for serious side effects, including suicidal tendencies. The numbers of patients who have used Neurontin for treatment of a non-FDA approved use are estimated at 40% of all prescriptions. Neurontin remains on the market for its FDA approved purposes.